ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.62%
- Poor long term growth as Operating profit has grown by an annual rate 27.23% of over the last 5 years
- The company is Net-Debt Free
2
With ROE of 11.65%, it has a Very Expensive valuation with a 23.76 Price to Book Value
- Over the past year, while the stock has generated a return of 240.11%, its profits have risen by 140% ; the PEG ratio of the company is 1.5
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Biocytogen Pharmaceuticals (Beijing) Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
240.11%
6.43
81.06%
Hang Seng Hong Kong
8.76%
0.45
19.63%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
57.35%
EBIT Growth (5y)
27.23%
EBIT to Interest (avg)
-6.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.86
Sales to Capital Employed (avg)
21.40
Tax Ratio
12.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.08%
ROE (avg)
0.62%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
204
Industry P/E
Price to Book Value
23.76
EV to EBIT
104.42
EV to EBITDA
57.37
EV to Capital Employed
24.20
EV to Sales
18.05
PEG Ratio
1.46
Dividend Yield
NA
ROCE (Latest)
23.18%
ROE (Latest)
11.65%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
NET SALES(Q)
Highest at HKD 829.66 MM
RAW MATERIAL COST(Y)
Fallen by -11.14% (YoY
CASH AND EQV(HY)
Highest at HKD 1,765.56 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -30.66 %
NET PROFIT(Q)
Highest at HKD 91.19 MM
EPS(Q)
Highest at HKD 0.34
-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Net Sales
Highest at HKD 829.66 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (HKD MM)
Net Sales
At HKD 829.66 MM has Grown at 34.19%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (HKD MM)
Net Profit
Highest at HKD 91.19 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
EPS
Highest at HKD 0.34
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (HKD)
Cash and Eqv
Highest at HKD 1,765.56 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -30.66 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -11.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
